Business Of Biotech
Funding Alzheimer's Tx Dev with ADDF's Karen Harris
Apr 1, 2024
Karen Harris, CFO of ADDF, shares insights on funding Alzheimer's therapies and the value of venture philanthropy in biotech. She discusses the challenges in securing funding, the shift towards aging biology in treatments, and the investments in CNS-related work. The episode delves into the relationship between anti-aging research and neurodegenerative diseases, emphasizing the importance of Alzheimer's research and venture philanthropy in biotech funding.
40:16
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- ADDF implements a unique venture philanthropy model, directly investing in biotechs to accelerate Alzheimer's drug development.
- ADDF channels support into novel Alzheimer's therapeutics, emphasizing precision medicine and combination therapies for impactful treatments.
Deep dives
Venture Philanthropy and Biotech Funding
Venture philanthropy emerges as a bright spot in the biotech funding landscape. Focused on accelerating drug discovery for Alzheimer's disease, the Alzheimer's Drug Discovery Foundation (ADDF) stands out. Founded by the Lauder family and bolstered by prominent supporters like Bill Gates and Jeff Bezos, ADDF functions as a venture philanthropy fund, investing in biotechs developing Alzheimer's therapeutics with returns reinvested into the fund.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
